Overview

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

This randomized phase II trial is studying how well giving selumetinib together with or without temsirolimus works in treating patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be removed by surgery. Selumetinib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving selumetinib together with temsirolimus is more effective than giving selumetinib alone.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

National Comprehensive Cancer Network

Treatments:

Everolimus
Sirolimus